Clinical Trials on Non Small Cell Lung Cancer Recurrent

Total 8603 results

M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
NeoImmuneTech
Roche Pharma AG

Active, not recruiting

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung Carcinoma

United States
University Health Network, Toronto
Pfizer

Recruiting

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | ROS1 Gene Rearrangement | MET Activating Mutation | MET Amplification

Canada
European Institute of Oncology
University of Rome Tor Vergata

Recruiting

Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II | Lung Cancer Diagnosis

Italy
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
National Cancer Institute (NCI)

Terminated

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Large Cell Lung Carcinoma | Bronchioloalveolar Lung Carcinoma

United States
Shirish Gadgeel
Merck Sharp & Dohme LLC

Withdrawn

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC (HFHS 21-01)

Non Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma
Institut Cancerologie de l'Ouest

Recruiting

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (TRAILOCLORI01)

Metastatic Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer

France
Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Non-squamous Non-small Cell Lung Cancer

China
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
Sanofi

Active, not recruiting

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)

Non-squamous Non-small Cell Lung Cancer

Belgium, Italy, Spain, Japan, United States, France, Turkey
Boehringer Ingelheim

Completed

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

Non-squamous, Non-Small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Intergroupe Francophone de Cancerologie Thoracique

Completed

Paclitaxel-bevacizumab in Advanced Lung Cancer (Ultimate)

Non-squamous Non-small Cell Lung Cancer

France
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Unknown

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Non-squamous Non-small Cell Lung Cancer
Jian Fang
Peking University First Hospital; Peking University Third Hospital; The Second...

Unknown

Apatinib in Advanced Non-squamous，NSCLC

Non-squamous Non-Small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)

Non-Squamous Non-Small Cell Lung Cancer

Spain
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Non-Squamous Non-Small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Hoffmann-La Roche

Terminated

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (STAR)

Non-Squamous Non-Small Cell Lung Cancer

Romania
Genentech, Inc.

Completed

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Spain, France, United States, United Kingdom, Latvia, Italy, Israel, Argentina, Germany
Abramson Cancer Center of the University of Pennsylvania

Active, not recruiting

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Non-small Cell Lung Cancer

United States
Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center

Terminated

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB/IV

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung Cancer

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Puerto Rico
Biocad

Unknown

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (DOMINUS)

Non Small Cell Lung Cancer Stage IIIB | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Russian Federation, Belarus
Hoffmann-La Roche

Completed

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Non-Small Cell Lung Cancer, Lung Cancer, Cancer

China
National Cancer Institute (NCI)

Terminated

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage II Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom

Clinical Trials on Non Small Cell Lung Cancer Recurrent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations